CSPC RECOMGEN PHARMACEUTICAL GUANGZHOU CO. is an innovative biopharmaceutical enterprise focused on the research and development of serum-free continuous animal cell culture technology and new biological drugs. The company has successfully developed a new generation of thrombolytic drug, rhTNK tPA (recombinant human TNK tissue-type plasminogen activator), which is used for the treatment of acute myocardial infarction (AMI). This drug has been included in the National Drug Reimbursement List as of April 2, 2022, highlighting its significance in the medical field.

The company primarily serves healthcare providers and hospitals that treat cardiovascular diseases, specifically targeting the acute myocardial infarction market. Their business model revolves around the development, production, and distribution of advanced biopharmaceuticals. Revenue is generated through the sale of these specialized drugs, which are critical in emergency medical treatments.

Keywords: biopharmaceuticals, thrombolytic drugs, rhTNK tPA, acute myocardial infarction, serum-free culture, cardiovascular treatment, innovative R&D, healthcare providers, drug reimbursement, biotechnology.